Sara M. Tolaney, MD, MPH

Sara M. Tolaney, MD, MPH, discusses sequencing strategies in metastatic HER2-positive breast cancer.

Sara M. Tolaney, MD, MPH, discusses remaining questions with CDK4/6 inhibitors in hormone receptor–positive, HER2-negative metastatic breast cancer.

Sara M. Tolaney, MD, MPH, discusses remaining sequencing questions in breast cancer.

Sara M. Tolaney, MD, MPH, associate director, Susan F. Smith’s Center for Women’s Cancers, director, Clinical Trials, Breast Oncology, senior physician, Dana-Farber Cancer Institute, and assistant professor of medicine at Harvard Medical School, discusses considerations for adjuvant therapy in patients with early-stage HER2-positive breast cancer.

Sara M. Tolaney, MD, MPH, discusses novel approaches in treating patients with HER2-positive breast cancer.

Sara M. Tolaney, MD, MPH, discusses the advantages of circulating tumor DNA versus tissue biopsy in breast cancer.

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the presence of PIK3CA mutations and ESR1 mutations in patients with breast cancer enrolled in the phase III MONARCH 2 trial.

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses recent advances in the treatment of patients with hormone receptor-positive breast cancer.

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, reflects on data from the PERSEPHONE trial in HER2-positive breast cancer.

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses unmet needs in the treatment of patients with estrogen receptor (ER)-positive breast cancer.

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the role of chemotherapy in the treatment of patients with HER2-positive breast cancer.

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses selecting patients with estrogen receptor (ER)-positive breast cancer for treatment with CDK4/6 inhibitors.

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the phase Ib results of abemaciclib (Verzenio) plus pembrolizumab (Keytruda) for hormone receptor-positive, HER2-negative metastatic breast cancer.

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the evolution of adjuvant treatment for patients with HER2-positive breast cancer.

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the ATEMPT trial for patients with HER2-positive breast cancer.

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the current treatment landscape for patients with HER2-positive breast cancer.

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses neoadjuvant HER2-directed therapy for patients with breast cancer.

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses neratinib (Nerlynx) in HER2-positive breast cancer.

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses neoadjuvant HER2-directed therapy.

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the results of a phase II trial exploring the efficacy of abemaciclib as a treatment of brain metastases that are secondary in patients with hormone receptor (HR)-positive,HER2-negative breast cancer.

Sara M. Tolaney, MD, MPH, associate director, Clinical Research, Breast Oncology, Susan F. Smith Center for Women's Cancers, senior physician, instructor in Medicine, Harvard Medical School, discusses a phase Ib/II trial exploring eribulin mesylate (Halaven) in combination with pembrolizumab (Keytruda) in patients with metastatic triple-negative breast cancer (TNBC).

Growing attempts to develop biomarkers to guide therapy within triple-negative breast cancer may lead to more effective regimens or to novel therapeutic targets.

Sara M. Tolaney, MD, MPH, physician, instructor in medicine, Harvard Medical School, medical oncologist, Dana-Farber Cancer Institute, discusses adding platinum-based therapy to the neoadjuvant setting for the treatment of patients with triple-negative breast cancer.

Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute and Brigham and Women's Hospital, discusses trials investigating cabozantinib in breast cancer.